Research programme: breast cancer therapeutics - Theraclone Sciences
Latest Information Update: 05 May 2014
At a glance
- Originator Theraclone Sciences
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 24 Apr 2014 Preclinical in Breast cancer (triple negative and endocrine treatment resistant) in USA (Parenteral)